At least nine distinct polymorphic forms of apolipoproteins are known to exist in tissues and serum, mainly as protein components of lipoprotein particles. The apolipoproteins generally act as stablizers of the intact particle. Quantitative measurements of HDL, LDL and VLDL particles in human serum are often used to estimate an individual’s relative risk of coronary heart disease. In addition, quantitative immunological measurements of certain apolipoproteins (especially A-1 and B) have been suggested to be more accurate estimators of coronary heart disease than measurements of lipoprotein particles (especially HDL and LDL). Our apolipoproteins are derived from human plasma by density gradient ultracentrifugation and HPLC. Goats are used to generate apolipoprotein antibodies which are purified by immunoaffinity chromatography and then extensively cross-adsorbed to generate precise specificities. Apolipoprotein antibodies have been used to determine that atherosclerotic lesions in the human aorta contain considerable amounts of lipoproteins. These lipoproteins were observed to be complexed with components of the extracellular matrix (especially LDL and proteoglycans). The role of these matrix-lipoprotein complexes is not entirely clear. However, animal models of atherosclerosis have shown that increased cellular proliferation and increased production of extracellular matrix components occur following injury to the intimal layer of the aorta. All anti-apolipoprotein antibodies are affinity purified and extensively cross-adsorbed to remove any unwanted reactivities. Less than 1% cross-reactivity is typically seen when assayed by ELISA against a panel of human and mouse apolipoproteins and related serum proteins. All apolipoprotein antibodies are supplied in liquid form.
Specificity: Antibody will react with human type C-I apolipoprotein.
Dilutions: Western Blot 1:5,000 to 1:10,000 ELISA 1:5,000 to 1:10,000
- Harmless-use normal precautions
- Exercise normal care
- Store at 4 degrees celsius;Cold pack shipment